10x Genomics Inc., founded in 2012 and headquartered in Pleasanton, California, United States, provides advanced genomic analysis systems that focus on single-cell and spatial genomics. The company’s primary revenue comes from its flagship Chromium system and recurring consumable sales, supporting cutting-edge research across academic and clinical settings. Led by CEO Serge Saxena since 2019, it holds a strong market position with significant technological advantages. Future growth is being driven by innovations in next-generation platforms and expanded market strategies.
Financial Statements
In thousands, USD
FY 2025
FY 2024
FY 2023
FY 2022
Total Revenues
642,823
610,785
618,727
516,409
Cost of Sales
198,942
196,303
209,414
120,386
Gross Profit
443,881
414,482
409,313
396,023
Selling, General & Administrative Expenses
316,134
344,343
343,330
298,300
Research & Development Expenses
238,632
264,698
270,332
265,667
Other Operating Expenses
49,900
—
60,980
—
Operating Profit
(60,985)
(194,559)
(265,329)
(167,944)
Interest and Investment Income
20,048
18,930
16,885
6,647
Interest Expense
—
(4)
(33)
(476)
Non-Operating Income
1,030
(2,067)
(286)
(198)
Total Non-Operating Income
21,078
16,859
16,566
5,973
Income Before Provision for Income Taxes
(39,907)
(177,700)
(248,763)
(161,971)
Provision for Income Taxes
3,637
4,927
6,336
4,029
Consolidated Net Income
(43,544)
(182,627)
(255,099)
(166,000)
Net Income Attributable to Common Shareholders
(43,544)
(182,627)
(255,099)
(166,000)
Basic EPS
-0.35
-1.52
-2.18
-1.46
Diluted EPS
-0.35
-1.52
-2.18
-1.46
Basic Weighted Average Shares Outstanding
124,750
120,452
117,165
113,859
Diluted Weighted Average Shares Outstanding
124,750
120,452
117,165
113,859
Shares Outstanding
127,691
122,292
119,095
115,195
FY 2025
FY 2024
FY 2023
FY 2022
Cash and Cash Equivalents
473,966
344,067
359,284
219,746
Short-Term Investments
49,443
49,335
29,411
212,871
Total Cash and Cash Equivalents
523,409
393,402
388,695
432,617
Accounts Receivable
47,013
87,862
114,832
104,211
Other Receivables
35,480
606
—
—
Total Trade Receivables
82,493
88,468
114,832
104,211
Inventories
56,341
83,107
73,706
81,629
Other Current Assets
22,208
19,410
18,789
16,578
Total Current Assets
684,451
584,387
596,022
635,035
Net Property, Plant & Equipment
287,161
309,938
344,932
359,210
Net Intangible Assets
62,329
15,671
16,616
22,858
Goodwill
4,511
4,511
4,511
4,511
Other Long-Term Assets
2,913
4,129
3,062
7,366
Total Assets
1,041,370
918,636
965,143
1,028,980
Accounts Payable
12,733
12,909
15,738
21,599
Accrued Expenses
82,471
74,780
86,753
92,454
Current Portion of Leases
10,985
9,286
11,521
9,037
Unearned Revenue
23,902
20,658
13,150
7,867
Other Current Liabilities
23,363
—
—
—
Total Current Liabilities
153,454
117,633
127,162
130,957
Leases
73,376
73,327
83,849
86,139
Other Long-Term Liabilities
18,209
17,542
13,089
6,141
Total Long-Term Liabilities
91,585
90,869
96,938
92,280
Total Liabilities
245,039
208,502
224,100
223,237
Common Stock
2
2
2
2
Additional Paid-in Capital
2,306,690
2,177,670
2,025,890
1,839,400
Accumulated Other Comprehensive Income
225
(493)
(429)
(4,335)
Retained Earnings
(1,510,590)
(1,467,050)
(1,284,420)
(1,029,320)
Total Common Shareholders' Equity
796,326
710,134
741,043
805,743
Total Shareholders' Equity
796,326
710,134
741,043
805,743
Total Liabilities and Shareholders' Equity
1,041,370
918,636
965,143
1,028,980
FY 2025
FY 2024
FY 2023
FY 2022
Net Income
(43,544)
(182,627)
(255,099)
(166,000)
Depreciation & Amortization
43,816
43,708
43,619
33,006
Share-Based Compensation Expense
109,118
140,749
166,950
136,848
Other Adjustments
1,721
3,580
11,990
1,957
Changes in Trade Receivables
6,440
26,951
(10,613)
(18,948)
Changes in Inventories
27,953
(9,777)
7,871
(21,192)
Changes in Accounts Payable
(2,126)
(3,354)
(6,017)
5,858
Changes in Accrued Expenses
2,494
(9,082)
25,664
4,450
Changes in Unearned Revenue
746
11,209
10,932
3,350
Changes in Other Operating Activities
(10,568)
(14,693)
(10,494)
(12,935)
Cash from Operating Activities
136,050
6,664
(15,197)
(33,606)
Capital Expenditure
(5,935)
(12,393)
(48,601)
(131,661)
Purchases of Intangible Assets
—
(1,000)
(923)
—
Purchases of Investments
(123,435)
(48,876)
—
(282,871)
Proceeds from Sale of Investments
125,200
29,638
183,016
67,645
Payments for Business Acquisitions
(9,268)
—
—
(4,000)
Cash from Investing Activities
(13,438)
(32,631)
133,492
(350,887)
Issuance of Common Shares
6,803
10,914
19,483
21,226
Net Issuance / (Repurchases) of Common Shares
6,803
10,914
19,483
21,226
Other Financing Activities
—
—
(5,814)
(5,409)
Cash from Financing Activities
6,803
10,914
13,669
15,817
Effect of Exchange Rate Changes on Cash and Cash Equivalents
484
(164)
(33)
(44)
Increase / (Decrease) in Cash, Cash Equivalents and Restricted Cash